Newsbenzinga
Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis; Study Did Not Meet Key Efficacy Objectives
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…